Tumour-associated macrophage-derived interleukin-1 mediates glioblastoma-associated cerebral oedema | Zendy

Cameron J. Herting | Zendy; Zhihong Chen | Zendy; Victor Maximov | Zendy; Alyssa Duffy | Zendy; Frank Szulzewsky | Zendy; Dmitry M. Shayakhmetov | Zendy; Dolores Hambardzumyan | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Tumour-associated macrophage-derived interleukin-1 mediates glioblastoma-associated cerebral oedema

Author(s) -

Cameron J. Herting,

Zhihong Chen,

Victor Maximov,

Alyssa Duffy,

Frank Szulzewsky,

Dmitry M. Shayakhmetov,

Dolores Hambardzumyan

Publication year - 2019

Publication title -

brain

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.142

H-Index - 336

eISSN - 1460-2156

pISSN - 0006-8950

DOI - 10.1093/brain/awz331

Subject(s) - dexamethasone , medicine , glioblastoma , immunotherapy , interleukin 6 , interleukin , microglia , macrophage , pharmacology , neuroscience , immunology , cancer research , cytokine , inflammation , chemistry , biology , immune system , biochemistry , in vitro

Dexamethasone is used to manage cerebral oedema in patients with glioblastoma, despite significant drawbacks. Herting et al. show that dexamethasone reduces oedema via inhibition of interleukin-1 signalling. They highlight a likely interaction between dexamethasone and immunotherapy, and propose that specific interleukin-1 inhibition may be preferable to dexamethasone for managing oedema.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research